M- J Zhang1, C- Z Zhang1, W- J Du1, X- Z Yang1, Z- P Chen2. 1. Department of Gastroenterology, Shandong Provincial Qianfoshan Hospital, Shandong University, No.16766 Jingshi Road, Jinan, 250014, China. 2. Department of Gastroenterology, Shandong Provincial Qianfoshan Hospital, Shandong University, No.16766 Jingshi Road, Jinan, 250014, China. chenziping1966@126.com.
Abstract
OBJECTIVE: ATPase family, AAA domain containing 2 (ATAD2) has been found overexpressed in various cancer types and correlated with malignant status and poor prognosis. However, little is known about the clinical significance of ATAD2 in gastric cancer patients. The aim of this study was to explore the clinical and prognostic significance of ATAD2 in gastric cancer. METHODS: The mRNA and protein levels expression of ATAD2 were detected in clinical tissue samples by qRT-PCR and immunohistochemistry, respectively. We examined the ATAD2 protein expression by immunohistochemistry. Furthermore, we analyzed the association between ATAD2 expression and clinicopathological features including prognosis in 166 gastric cancer samples. RESULTS: In our results, ATAD2 mRNA and protein were highly expressed in gastric cancer samples. ATAD2 overexpression was correlated with advanced clinical stage, tumor depth, lymph node metastasis, and distant metastasis. According to the survival analysis, ATAD2 protein overexpression was a poor independent prognostic factor for gastric cancer patients. CONCLUSIONS: In summary, ATAD2 could serve as a prognostic biomarker for gastric cancer patients.
OBJECTIVE: ATPase family, AAA domain containing 2 (ATAD2) has been found overexpressed in various cancer types and correlated with malignant status and poor prognosis. However, little is known about the clinical significance of ATAD2 in gastric cancerpatients. The aim of this study was to explore the clinical and prognostic significance of ATAD2 in gastric cancer. METHODS: The mRNA and protein levels expression of ATAD2 were detected in clinical tissue samples by qRT-PCR and immunohistochemistry, respectively. We examined the ATAD2 protein expression by immunohistochemistry. Furthermore, we analyzed the association between ATAD2 expression and clinicopathological features including prognosis in 166 gastric cancer samples. RESULTS: In our results, ATAD2 mRNA and protein were highly expressed in gastric cancer samples. ATAD2 overexpression was correlated with advanced clinical stage, tumor depth, lymph node metastasis, and distant metastasis. According to the survival analysis, ATAD2 protein overexpression was a poor independent prognostic factor for gastric cancerpatients. CONCLUSIONS: In summary, ATAD2 could serve as a prognostic biomarker for gastric cancerpatients.
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Elaine Y C Hsia; Ekaterina V Kalashnikova; Alexey S Revenko; June X Zou; Alexander D Borowsky; Hong-Wu Chen Journal: Mol Cancer Res Date: 2010-02-02 Impact factor: 5.852
Authors: June X Zou; Linlang Guo; Alexey S Revenko; Clifford G Tepper; Abigael T Gemo; Hsing-Jien Kung; Hong-Wu Chen Journal: Cancer Res Date: 2009-03-24 Impact factor: 12.701
Authors: Bodour Salhia; Jeff Kiefer; Julianna T D Ross; Raghu Metapally; Rae Anne Martinez; Kyle N Johnson; Danielle M DiPerna; Kimberly M Paquette; Sungwon Jung; Sara Nasser; Garrick Wallstrom; Waibhav Tembe; Angela Baker; John Carpten; Jim Resau; Timothy Ryken; Zita Sibenaller; Emanuel F Petricoin; Lance A Liotta; Ramesh K Ramanathan; Michael E Berens; Nhan L Tran Journal: PLoS One Date: 2014-01-29 Impact factor: 3.240
Authors: Maria B Raeder; Even Birkeland; Jone Trovik; Camilla Krakstad; Shyemaa Shehata; Steven Schumacher; Travis I Zack; Antje Krohn; Henrica Mj Werner; Susan E Moody; Elisabeth Wik; Ingunn M Stefansson; Frederik Holst; Anne M Oyan; Pablo Tamayo; Jill P Mesirov; Karl H Kalland; Lars A Akslen; Ronald Simon; Rameen Beroukhim; Helga B Salvesen Journal: PLoS One Date: 2013-02-05 Impact factor: 3.240
Authors: Jamie C Gay; Brian E Eckenroth; Chiara M Evans; Cassiano Langini; Samuel Carlson; Jonathan T Lloyd; Amedeo Caflisch; Karen C Glass Journal: Proteins Date: 2018-12-27
Authors: Vicente Planells-Palop; Ali Hazazi; Julia Feichtinger; Jana Jezkova; Gerhard Thallinger; Naif O Alsiwiehri; Mikhlid Almutairi; Lee Parry; Jane A Wakeman; Ramsay J McFarlane Journal: Mol Cancer Date: 2017-04-26 Impact factor: 27.401
Authors: Duncan C Miller; Mathew P Martin; Santosh Adhikari; Alfie Brennan; Jane A Endicott; Bernard T Golding; Ian R Hardcastle; Amy Heptinstall; Stephen Hobson; Claire Jennings; Lauren Molyneux; Yvonne Ng; Stephen R Wedge; Martin E M Noble; Celine Cano Journal: Org Biomol Chem Date: 2018-03-14 Impact factor: 3.876
Authors: Seong Joo Koo; Amaury E Fernández-Montalván; Volker Badock; Christopher J Ott; Simon J Holton; Oliver von Ahsen; Joern Toedling; Sarah Vittori; James E Bradner; Mátyás Gorjánácz Journal: Oncotarget Date: 2016-10-25
Authors: Xiangyu Meng; Lu Wang; Bo Zhu; Jun Zhang; Shuai Guo; Qiang Li; Tao Zhang; Zhichao Zheng; Gang Wu; Yan Zhao Journal: Biomed Res Int Date: 2020-05-05 Impact factor: 3.411